Mercks Controversial HPV Vaccine Spurs $100 Million Capital Investment in Virginia
Mercks Controversial HPV Vaccine Spurs $100 Million Capital Investment in Virginia
The current $57 million expansion follows a $40 million first phase that was completed last year at the plant), where a portion of the Gardasil production process...
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- Samsung Biologics Constructing ADC Plant in South Korea
- Data Center Activity Propels Virginia to $12.7 Billion of Projects Under Co...
- Pharma Company Zoetis Signs PPA with Scout Clean Energy to Support Growing ...
- China's Rongsheng Petrochemical Ups Role in Polyester Chips
- Suffolk Construction Has Hand in $1.9 Billion Worth of Projects
Quick Links
- Home
- About Us
- Contact Us
- For Traders
Global Market Intelligence
- GMI Database Platform
- GMI Platform Tools
- Industry Coverage
- Analytics & Insights
- Advertising
